.svg){kind=small}
Association of Myocarditis With BNT162b2 Messenger RNA COVID-19 Vaccine in a Case Series of Children
August 10, 2021
Dionne et al., 2021
JAMA
This study was a case series of children younger than 19 years hospitalized with myocarditis within 30 days of BNT162b2 messenger RNA COVID-19 vaccine. The setting was a single-center pediatric referral facility, and admissions occurred between May 1 and July 15, 2021. Fifteen patients (14 male patients [93%]; median age, 15 years were hospitalized for management of myocarditis after receiving the BNT162b2 (Pfizer) vaccine.
Dionne, A., Sperotto, F., Chamberlain, S., Baker, A. L., Powell, A. J., Prakash, A., Castellanos, D. A., Saleeb, S. F., de Ferranti, S. D., Newburger, J. W., & Friedman, K. G. (2021). Association of Myocarditis With BNT162b2 Messenger RNA COVID-19 Vaccine in a Case Series of Children. JAMA Cardiology, 6(12), 1446. https://doi.org/10.1001/jamacardio.2021.3471
